Iovance Biotherapeutics (IOVA) Misses Q4 EPS by 1c

Iovance Biotherapeutics (NASDAQ: IOVA) reported Q4 EPS of ($0.18), $0.01 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $86.71 million versus the consensus estimate of $82.03 million.

For earnings history and earnings-related data on Iovance Biotherapeutics (IOVA) click here.

You May Also Be Interested In

• Mosaic (MOS), Others Lower Following Trump Post on Potash from Belarus
• Coinbase (COIN) call put ratio 2.3 calls to 1 put as share price up 5.6%
• Strategy (MSTR) call put ratio 2.3 calls to 1 put as share price up 8.3%